Given the precedence in targeting ERBB2-amplified/HER2-expressing carcinosarcoma, we focused our attention on FGFR1 copy number gain/amplification as another potentially targetable alteration in carcinosarcoma. This evidence concerns the gene FGFR1 and carcinosarcoma.